Subcommittee on Cell and Gene Therapy Products Produced in vivo

Background

In recent years, the progress in the development of gene therapy has realized ex vivo gene therapy (in which genetically modified target tissues/cells once removed from the body and administered back to the patient), such as chimeric antigen receptor (CAR)-T cell therapy. Meanwhile, in vivo gene therapy (in which a gene delivery vector is directly administered to patients) is also being attempted to create CAR-T in vivo.
The subcommittee discusses points to consider in the development and evaluation of novel in vivo gene therapy, focusing on the target specificity of various gene modification tools, based on the clinical experience of CAR-T and other gene therapies.

Member List

Member List of the Subcommittee on Cell and Gene Therapy Products Produced in vivo